MedTrace Logo

Eltrombopag for Peripheral Blood Stem Cell Harvest

NCT05961410 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-10-18

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are:

* Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest.
* Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization.

Participants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.

Conditions

  • Lymphoma
  • Peripheral Blood Stem Cell Transplantation

Interventions

DRUG

Eltrombopag olamine

Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ta-Chuan Yu, MD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-03-31
Completion
2026-03-01
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961410 on ClinicalTrials.gov